(e,z)-farnesol

(e,z)-farnesol is a lipid of Prenol Lipids (PR) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 3613 references associated with (e,z)-farnesol in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for (e,z)-farnesol

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with (e,z)-farnesol

MeSH term MeSH ID Detail
Pancreatic Neoplasms D010190 77 associated lipids
Osteosarcoma D012516 50 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Glioblastoma D005909 27 associated lipids
Fibrosis D005355 23 associated lipids
HIV Infections D015658 20 associated lipids
Nephritis D009393 19 associated lipids
Leukemia, Myeloid, Acute D015470 19 associated lipids
Candidiasis, Oral D002180 11 associated lipids
Per page 10 20 50 | Total 23

PubChem Biomolecular Interactions and Pathways

All references with (e,z)-farnesol

Download all related citations
Per page 10 20 50 100 | Total 813
Authors Title Published Journal PubMed Link
Andres DA et al. Rapid identification of cysteine-linked isoprenyl groups by metabolic labeling with [3H]farnesol and [3H]geranylgeraniol. 1999 Methods Mol. Biol. pmid:10399149
Weisz B et al. A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice. 1999 Oncogene pmid:10353601
Egozi Y et al. Growth inhibition of ras-dependent tumors in nude mice by a potent ras-dislodging antagonist. 1999 Int. J. Cancer pmid:10074926
Machida K et al. Farnesol-induced growth inhibition in Saccharomyces cerevisiae by a cell cycle mechanism. 1999 Microbiology (Reading, Engl.) pmid:10075411
Fisher JE et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. 1999 Proc. Natl. Acad. Sci. U.S.A. pmid:9874784
Parmryd I and Dallner G In vivo prenylation of rat proteins: modification of proteins with penta- and hexaprenyl groups. 1999 Arch. Biochem. Biophys. pmid:10190969
Luft UC et al. Farnesol blocks the L-type Ca2+ channel by targeting the alpha 1C subunit. 1999 Arterioscler. Thromb. Vasc. Biol. pmid:10195923
Roullet JB et al. Modulation of neuronal voltage-gated calcium channels by farnesol. 1999 J. Biol. Chem. pmid:10464274
Parmryd I et al. Protein prenylation in spinach chloroplasts. 1999 Proc. Natl. Acad. Sci. U.S.A. pmid:10468564
Gibbs BS et al. Novel farnesol and geranylgeraniol analogues: A potential new class of anticancer agents directed against protein prenylation. 1999 J. Med. Chem. pmid:10508429
Lin HP et al. Localization of isoprenylated antigen of hepatitis delta virus by anti-farnesyl antibodies. 1999 J. Gen. Virol. pmid:9934689
Niv H et al. Membrane interactions of a constitutively active GFP-Ki-Ras 4B and their role in signaling. Evidence from lateral mobility studies. 1999 J. Biol. Chem. pmid:9880539
Weissmann N et al. Evidence for a role of protein kinase C in hypoxic pulmonary vasoconstriction. 1999 Am. J. Physiol. pmid:9887060
Hanley K et al. Fetal epidermal differentiation and barrier development In vivo is accelerated by nuclear hormone receptor activators. 1999 J. Invest. Dermatol. pmid:10571735
Goodwin TE et al. African elephant sesquiterpenes. 1999 J. Nat. Prod. pmid:10579877
Machida K and Tanaka T Farnesol-induced generation of reactive oxygen species dependent on mitochondrial transmembrane potential hyperpolarization mediated by F(0)F(1)-ATPase in yeast. 1999 FEBS Lett. pmid:10580101
Hirohata S et al. Inhibition of human B cell activation by a novel nonsteroidal anti-inflammatory drug, indometacin famesil. 1999 Immunopharmacology pmid:10598881
Shack S et al. Activation of the cholesterol pathway and Ras maturation in response to stress. 1999 Oncogene pmid:10557091
Thai L et al. Farnesol is utilized for isoprenoid biosynthesis in plant cells via farnesyl pyrophosphate formed by successive monophosphorylation reactions. 1999 Proc. Natl. Acad. Sci. U.S.A. pmid:10557276
Jansen B et al. Novel Ras antagonist blocks human melanoma growth. 1999 Proc. Natl. Acad. Sci. U.S.A. pmid:10570191
Elad G et al. Targeting of K-Ras 4B by S-trans,trans-farnesyl thiosalicylic acid. 1999 Biochim. Biophys. Acta pmid:10590312
Reif S et al. The Ras antagonist, farnesylthiosalicylic acid (FTS), inhibits experimentally-induced liver cirrhosis in rats. 1999 J. Hepatol. pmid:10604579
Hartmann MA et al. Metabolism of farnesyl diphosphate in tobacco BY-2 cells treated with squalestatin. 2000 Biochem. Soc. Trans. pmid:11171211
Beedle AM and Zamponi GW Block of voltage-dependent calcium channels by aliphatic monoamines. 2000 Biophys. J. pmid:10866952
Mo H et al. Farnesyl anthranilate suppresses the growth, in vitro and in vivo, of murine B16 melanomas. 2000 Cancer Lett. pmid:10936674
Toró A et al. Transannular Diels-Alder studies on the asymmetric total synthesis of chatancin: the pyranophane approach. 2000 Org. Lett. pmid:10964353
Yang W et al. Protein farnesylation is critical for maintaining normal cell morphology and canavanine resistance in Schizosaccharomyces pombe. 2000 J. Biol. Chem. pmid:10617635
Hanley K et al. Farnesol stimulates differentiation in epidermal keratinocytes via PPARalpha. 2000 J. Biol. Chem. pmid:10753967
Bringmann A et al. Farnesol modulates membrane currents in human retinal glial cells. 2000 J. Neurosci. Res. pmid:11054809
Halaschek-Wiener J et al. A novel Ras antagonist regulates both oncogenic Ras and the tumor suppressor p53 in colon cancer cells. 2000 Mol. Med. pmid:11055588
Xie H et al. Synthesis and biological evaluation of the geometric farnesylated analogues of the a-factor mating peptide of Saccharomyces cerevisiae. 2000 J. Org. Chem. pmid:11112575
Eskens FA et al. Farnesyl transferase inhibitors: current developments and future perspectives. 2000 Cancer Treat. Rev. pmid:11006134
Kloog Y and Cox AD RAS inhibitors: potential for cancer therapeutics. 2000 Mol Med Today pmid:11006529
Hemmerlin A and Bach TJ Farnesol-induced cell death and stimulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity in tobacco cv bright yellow-2 cells. 2000 Plant Physiol. pmid:10938345
Mussoni L et al. Fluvastatin inhibits basal and stimulated plasminogen activator inhibitor 1, but induces tissue type plasminogen activator in cultured human endothelial cells. 2000 Thromb. Haemost. pmid:10928471
Rioja A et al. Preferential induction of apoptosis of leukaemic cells by farnesol. 2000 FEBS Lett. pmid:10675556
Hemmer W et al. Axillary dermatitis from farnesol in a deodorant. 2000 Contact Derm. pmid:10727172
Rosado JA and Sage SO Farnesylcysteine analogues inhibit store-regulated Ca2+ entry in human platelets: evidence for involvement of small GTP-binding proteins and actin cytoskeleton. 2000 Biochem. J. pmid:10727417
Flach J et al. The mevalonate/isoprenoid pathway inhibitor apomine (SR-45023A) is antiproliferative and induces apoptosis similar to farnesol. 2000 Biochem. Biophys. Res. Commun. pmid:10733934
Villegas LF et al. (+)-epi-Alpha-bisabolol [correction of bisbolol] is the wound-healing principle of Peperomia galioides: investigation of the in vivo wound-healing activity of related terpenoids. 2001 J. Nat. Prod. pmid:11678668
Mizukami Y et al. Requirement of c-jun N-terminal kinase for apoptotic cell death induced by farnesyltransferase inhibitor, farnesylamine, in human pancreatic cancer cells. 2001 Biochem. Biophys. Res. Commun. pmid:11594773
Karussis D et al. The Ras-pathway inhibitor, S-trans-trans-farnesylthiosalicylic acid, suppresses experimental allergic encephalomyelitis. 2001 J. Neuroimmunol. pmid:11694313
Kim SY et al. Inhibition effect of new farnesol derivatives on all-trans-retinoic acid metabolism. 2001 Metab. Clin. Exp. pmid:11699057
Sari R et al. Impairment by lovastatin of neural relaxation of the rabbit sphincter of Oddi. 2001 Eur. J. Pharmacol. pmid:11734192
Rakhit RD et al. Role of G proteins and modulation of p38 MAPK activation in the protection by nitric oxide against ischemia-reoxygenation injury. 2001 Biochem. Biophys. Res. Commun. pmid:11527399
Nah J et al. Partial characterization of farnesyl and geranylgeranyl diphosphatases induced in rice seedlings by UV-C irradiation. 2001 Plant Cell Physiol. pmid:11522913
Katzav A et al. Treatment of MRL/lpr mice, a genetic autoimmune model, with the Ras inhibitor, farnesylthiosalicylate (FTS). 2001 Clin. Exp. Immunol. pmid:11737078
Wright MM et al. Uncoupling farnesol-induced apoptosis from its inhibition of phosphatidylcholine synthesis. 2001 J. Biol. Chem. pmid:11306571
Daily D et al. Glutaredoxin protects cerebellar granule neurons from dopamine-induced apoptosis by dual activation of the ras-phosphoinositide 3-kinase and jun n-terminal kinase pathways. 2001 J. Biol. Chem. pmid:11290748
Hornby JM et al. Quorum sensing in the dimorphic fungus Candida albicans is mediated by farnesol. 2001 Appl. Environ. Microbiol. pmid:11425711

Table of Content